Search

Your search keyword '"De Baetselier, Irith"' showing total 391 results
Start Over Author "De Baetselier, Irith"
391 results on '"De Baetselier, Irith"'

2. Potential determinants of the decline in mpox cases in Belgium: A behavioral, epidemiological and seroprevalence study

Author

De Vos, Elise, Van Gestel, Liesbeth, Brosius, Isabel, Kenyon, Chris, Vuylsteke, Bea, De Baetselier, Irith, Mariën, Joachim, Bangwen, Eugene, Couvreur, Simon, Lecompte, Amaryl, Van Beckhoven, Dominique, Hoorelbeke, Bart, Verstrepen, Babs E., Zaeck, Luca M., de Vries, Rory D., Geurts van Kessel, Corine H., Hens, Niel, Ariën, Kevin K., Vercauteren, Koen, Van Esbroek, Marjan, Van Dijck, Christophe, and Liesenborghs, Laurens

Published
2024
Full Text
View/download PDF

3. Antimicrobial-resistant Neisseria gonorrhoeae in Europe in 2020 compared with in 2013 and 2018: a retrospective genomic surveillance study

Author

Pleininger, Sonja, Stadlbauer, Silke, Indra, Alexander, De Baetselier, Irith, Vanden Berghe, Wim, Lecompte, Amaryl, Hunjak, Blaženka, Blažić, Tatjana Nemeth, Maikanti-Charalambous, Panayiota, Pieridou, Despo, Zákoucká, Hana, Žemličková, Helena, Hoffmann, Steen, Cowan, Susan, Schwartz, Lasse Jessen, Peetso, Rita, Epstein, Jevgenia, Viktorova, Jelena, Bercot, Beatrice, Bébéar, Cécile, Lot, Florence, Torvikoski, Jukka, Korhonen, Suvi, Buder, Susanne, Jansen, Klaus, Miriagou, Vivi, Siatravani, Eirini, Magaziotou, Ioanna, Paparizou, Eleni, Balla, Eszter, Dudás, Mária, Ásmundsdóttir, Lena Rós, Hauksdóttir, Guðrún Svanborg, Gudnason, Thorolfur, Thordardottir, Marianna, Colgan, Aoife, Crowley, Brendan, Saab, Sinéad, Keane, Maeve, Stefanelli, Paola, Carannante, Anna, Parodi, Patrizia, Pakarna, Gatis, Nikiforova, Raina, Bormane, Antra, Dimina, Elina, Barbara, Christopher, Mifsud, Francesca, Cassar, Robert, Haider, Julie, Van Dam, Alje, Van Benthem, Birgit, Visser, Maartje, Linde, Ineke, Kløvstad, Hilde, Caugant, Dominique, Bergheim, Thea, Młynarczyk-Bonikowska, Beata, Azevedo, Jacinta, Borrego, Maria-José, Nascimento, Marina Lurdes Ramos, Pavlik, Peter, Klavs, Irena, Murnik, Andreja, Kustec, Tanja, Vodičar, Polona Maver, Vázquez Moreno, Julio, Diaz, Asuncion, Abad Torreblanca, Raquel, Velicko, Inga, Unemo, Magnus, Golparian, Daniel, Cole, Michelle J, Sánchez-Busó, Leonor, Day, Michaela, Jacobsson, Susanne, Uthayakumaran, Thinushaa, Abad, Raquel, Caugant, Dominique A, Heuer, Dagmar, Aanensen, David M, and Bluemel, Benjamin

Published
2024
Full Text
View/download PDF

4. Effect of screening for Neisseria gonorrhoeae and Chlamydia trachomatis on incidence of these infections in men who have sex with men and transgender women taking HIV pre-exposure prophylaxis (the Gonoscreen study): results from a randomised, multicentre, controlled trial

Author

Vanbaelen, Thibaut, Tsoumanis, Achilleas, Florence, Eric, Van Dijck, Christophe, Huis in 't Veld, Diana, Sauvage, Anne-Sophie, Herssens, Natacha, De Baetselier, Irith, Rotsaert, Anke, Verhoeven, Veronique, Henrard, Sophie, Van Herrewege, Yven, Van den Bossche, Dorien, Goffard, Jean-Christophe, Padalko, Elizaveta, Reyniers, Thijs, Vuylsteke, Bea, Michel, Charlotte, Hayette, Marie-Pierre, Libois, Agnes, and Kenyon, Chris

Published
2024
Full Text
View/download PDF

5. Retrospective detection of asymptomatic monkeypox virus infections among male sexual health clinic attendees in Belgium

Author

De Baetselier, Irith, Van Dijck, Christophe, Kenyon, Chris, Coppens, Jasmine, Michiels, Johan, de Block, Tessa, Smet, Hilde, Coppens, Sandra, Vanroye, Fien, Bugert, Joachim Jakob, Girl, Philipp, Zange, Sabine, Liesenborghs, Laurens, Brosius, Isabel, van Griensven, Johan, Selhorst, Philippe, Florence, Eric, Van den Bossche, Dorien, Ariën, Kevin K., Rezende, Antonio Mauro, Vercauteren, Koen, and Van Esbroeck, Marjan

Published
2022
Full Text
View/download PDF

7. Characteristics of confirmed mpox cases among clinical suspects: A prospective single-centre study in Belgium during the 2022 outbreak

Author

Van Dijck, Christophe, Hens, Matilde, Van Esbroeck, Marjan, Brosius, Isabel, Liesenborghs, Laurens, Van Gestel, Liesbeth, Rutgers, Jojanneke, Kenyon, Chris, De Baetselier, Irith, Coppens, Jasmine, Van den Bossche, Dorien, Florence, Eric, Vercauteren, Koen, van Griensven, Johan, Bottieau, Emmanuel, Soentjens, Patrick, Berens-Riha, Nicole, van Henten, Saskia, Bracke, Stefanie, Vanbaelen, Thibaut, Vandenhoven, Leen, Van Frankenhuijsen, Maartje, Vandenbruaene, Marc, Huyst, Veerle, Wouters, Kristien, Apers, Ludwig, Kint, Ilse, Caluwaerts, Séverine, Vanroye, Fien, Verschueren, Jacob, and Ariën, Kevin

Published
2023
Full Text
View/download PDF

8. Europe-wide expansion and eradication of multidrug-resistant Neisseria gonorrhoeae lineages: a genomic surveillance study

Author

Pleininger, Sonja, Indra, Alexander, De Baetselier, Irith, Vanden Berghe, Wim, Hunjak, Blaženka, Blažić, Tatjana Nemeth, Maikanti-Charalambous, Panayiota, Pieridou, Despo, Zákoucká, Hana, Žemličková, Helena, Hoffmann, Steen, Cowan, Susan, Schwartz, Lasse Jessen, Peetso, Rita, Epstein, Jevgenia, Viktorova, Jelena, Ndeikoundam, Ndeindo, Bercot, Beatrice, Bébéar, Cécile, Lot, Florence, Buder, Susanne, Jansen, Klaus, Miriagou, Vivi, Rigakos, Georgios, Raftopoulos, Vasilios, Balla, Eszter, Dudás, Mária, Ásmundsdóttir, Lena Rós, Sigmundsdóttir, Guðrún, Hauksdóttir, Guðrún Svanborg, Gudnason, Thorolfur, Colgan, Aoife, Crowley, Brendan, Saab, Sinéad, Stefanelli, Paola, Carannante, Anna, Parodi, Patrizia, Pakarna, Gatis, Nikiforova, Raina, Bormane, Antra, Dimina, Elina, Perrin, Monique, Abdelrahman, Tamir, Mossong, Joël, Schmit, Jean-Claude, Mühlschlegel, Friedrich, Barbara, Christopher, Mifsud, Francesca, Van Dam, Alje, Van Benthem, Birgit, Visser, Maartje, Linde, Ineke, Kløvstad, Hilde, Caugant, Dominique, Młynarczyk-Bonikowska, Beata, Azevedo, Jacinta, Borrego, Maria-José, Nascimento, Marina Lurdes Ramos, Pavlik, Peter, Klavs, Irena, Murnik, Andreja, Jeverica, Samo, Kustec, Tanja, Vázquez Moreno, Julio, Diaz, Asuncion, Abad, Raquel, Velicko, Inga, Unemo, Magnus, Fifer, Helen, Shepherd, Jill, Patterson, Lynsey, Sánchez-Busó, Leonor, Cole, Michelle J, Spiteri, Gianfranco, Day, Michaela, Jacobsson, Susanne, Golparian, Daniel, Sajedi, Noshin, Yeats, Corin A, Abudahab, Khalil, Underwood, Anthony, Bluemel, Benjamin, and Aanensen, David M

Published
2022
Full Text
View/download PDF

9. Ciprofloxacin Concentrations in Food Could Select for Quinolone Resistance in Klebsiella pneumoniae : An In Vivo Study in Galleria mellonella.

Author

Panis, Nele, Gestels, Zina, Van Den Bossche, Dorien, De Baetselier, Irith, Abdellati, Said, Vanbaelen, Thibaut, de Block, Tessa, Santhini Manoharan-Basil, Sheeba, and Kenyon, Chris

Subjects
GREATER wax moth, KLEBSIELLA pneumoniae, CIPROFLOXACIN, FOOD of animal origin, AGAR plates
Abstract

Background: The use of antimicrobials to treat food animals leaves antimicrobial residues in foodstuffs. The World Health Organization (WHO) defines the acceptable daily intakes (ADIs) of these residues as the dose of these antimicrobials that is safe for an average human to consume on a daily basis. We hypothesized that the lowest dose of ciprofloxacin classified as safe by the WHO could select for ciprofloxacin-resistant strains of Klebsiella pneumoniae in a Galleria mellonella model. Objectives: We aimed to evaluate if the consumption of peri-ADI doses of ciprofloxacin could select for ciprofloxacin-resistant (Ser464Phe, GyrB, ciprofloxacin MIC of 4 µg/mL) compared to -susceptible (isogenic, ciprofloxacin MIC of 0.047 µg/mL) strains of K. pneumoniae in a Galleria mellonella model. Results: A significant increase was seen in the proportion of resistance for the 1× ADI and 1/10th ADI concentrations on day 2 compared to the positive control. Methods: A model of K. pneumoniae infection in G. mellonella larvae was used for the experiment. The larvae were inoculated with K. pneumoniae followed by 10× ADI, 1× ADI, 1/10th ADI, 1/100th ADI, and 1/1000th ADI doses of ciprofloxacin. The isolation of K. pneumoniae colonies was then performed on selective agar plates with and without ciprofloxacin (1 µg/mL). The proportion of colonies with ciprofloxacin resistance was then calculated for each group at 24 and 48 h. Conclusions: We found that, at 48 h, there was an enrichment of K. pneumoniae colonies with ciprofloxacin resistance in the larvae receiving 1× ADI and 1/10th ADI concentrations of ciprofloxacin. These results suggest that the ciprofloxacin MSCselect for K. pneumoniae in this model is 1/10th of the acceptable daily concentration (ADI) dose of ciprofloxacin, which is equivalent to 0.239 ng/µL. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

13. Antimicrobial Susceptibility of Commensal Neisseria spp. in Parents and Their Children in Belgium: A Cross-Sectional Survey

Author

Abdellati, Said, primary, Gestels, Zina, additional, Laumen, Jolein, additional, Van Dijck, Christophe, additional, De Baetselier, Irith, additional, de Block, TEssa, additional, Van den Bossche, Dorien, additional, Manoharan-Basil, Sheeba Santhini, additional, Kanesaka, Izumo, additional, Vanbaelen, Thibaut, additional, and Kenyon, Chris, additional

Published
2024
Full Text
View/download PDF

14. Trajectories of PrEP use among men who have sex with men: a pooled analysis of two prospective, observational cohort studies

Author

Jongen, Vita W., Reyniers, Thijs, Van Der Loeff, Maarten Schim, Smekens, Tom, Hoornenborg, Elske, Van Den Elshout, Mark, Zimmermann, Hanne, Coyer, Liza, Kenyon, Chris, De Baetselier, Irith, Davidovich, Udi, De Vries, Henry J.C., Prins, Maria, Laga, Marie, Vuylsteke, Bea, and Boyd, Anders

Subjects
Antiviral agents -- Dosage and administration, MSM (Men who have sex with men) -- Health aspects, HIV infection -- Prevention, Health
Abstract

: Introduction: Daily and event‐driven oral pre‐exposure prophylaxis (PrEP) reduce the risk of HIV acquisition. PrEP use can vary over time, yet little is known about the trajectories of PrEP use irrespective of the chosen PrEP regimens among men who have sex with men (MSM). Methods: Using data from a mobile, web‐based diary application collected daily from 17 August 2015 until 6 May 2018, we analysed PrEP use and sexual behaviour in two large cohorts, AMPrEP (Amsterdam, the Netherlands) and Be‐PrEP‐ared (Antwerp, Belgium). In both cohorts, participants could choose between daily and event‐driven oral PrEP every 3 months. We used group‐based trajectory modelling to identify trajectories of PrEP use over time and their determinants. In addition, we estimated the incidence rate of chlamydia, gonorrhoea and syphilis within these trajectories. Results: We included 516 MSM (n = 322 AMPrEP; n = 194 Be‐PrEP‐ared), of whom 24% chose event‐driven PrEP at PrEP initiation. Participants contributed 225,015 days of follow‐up (median = 508 days [IQR = 429−511]). Four distinct PrEP use trajectories were identified: ≤2 tablets per week (“low frequency,” 12% of the total population), 4 tablets per week (“variable,” 17%), “almost daily” (31%) and “always daily” (41%). Compared to participants with “low frequency” PrEP use, participants with “variable” (odds ratio [OR] = 2.18, 95% confidence interval [CI] = 1.04−4.60) and “almost daily” PrEP use were more often AMPrEP participants (OR = 2.64, 95% CI = 1.27−5.49). “Almost daily” PrEP users were more often employed (OR = 6.76, 95% CI = 2.10−21.75) and were younger compared to participants with “low frequency” PrEP use. In addition, the number of days on which anal sex occurred was lower among participants with “low frequency” PrEP use compared to the other groups (all p Conclusions: We uncovered four distinct PrEP use trajectories, pointing to different patterns of PrEP use in practice beyond the two‐regimen dichotomy. These trajectories were related to sexual behaviour and rates of sexually transmitted infection. Tailoring PrEP care according to different PrEP use patterns could be an important strategy to improve efficient PrEP delivery., INTRODUCTION Oral pre‐exposure prophylaxis (PrEP) is highly effective in reducing the risk of HIV acquisition when taken correctly [1–3]. Among cisgender men who have sex with men (MSM), PrEP can [...]

Published
2023
Full Text
View/download PDF

15. HIV pre-exposure prophylaxis for men who have sex with men in west Africa: a multicountry demonstration study

Author

Laurent, Christian, Yaya, Issifou, Ouedraogo, Sayouba, Granouillac, Bruno, Le Guicher, Gwenvael, Serrano, Laetitia, Peeters, Martine, Couderc, Clotilde, Spire, Bruno, Sagaon-Teyssier, Luis, Mora, Marion, Maradan, Gwenaëlle, Bourrelly, Michel, Mimi, Mohamed, Berenger, Cyril, Boyer, Sylvie, Rojas Castro, Daniela, Riegel, Lucas, Palvadeau, Paméla, Vuylsteke, Bea, De Baetselier, Irith, Reyniers, Thijs, Dembélé Keita, Bintou, Diallo, Fodié, Coulibaly, Alou, Maïga, Alassane Kader, Camara, Drissa, Diarra, Mahamadou, Ouologuem, Aly, Sangaré, Naboh, Keita, Abdoul Aziz, Cissé, Oumar, Traoré, Fodé, Ouary, Bréhima Abdrahamane, Kanta, Ibrahima, Anoma, Camille, Malan, Jean-Baptiste, Kotchi, Rachelle, Aka, Niamkey Thomas, Lokrou, Kpassou Julien, Coulibaly, Noufo Hamed, Koffi, Ekissi Jean Armel, N'guessan, Dibi Frédéric, Babo Yoro, Stéphane-Alain, Cissé, Adama, Dah, Ter Tiero Elias, Traoré, Issa, Rajaonarivelo, Camille, Ouedraogo, Fayçal Rodrique, Ouedraogo, Joseph, Coulibaly, Christian, Ouedraogo, Mamadou, Ilboudo, Ousseni, Traoré, Abdoulazziz, Comsiambo, Honoré, Mensah, Ephrem, Agboyibor, Mawuényégan Kouamivi, Attisso, Anani, Kokouba, Anouwarsadat, Badjassim, Aléda Mawuli, Agbomadji, Kouakou Kokouvi Selom, Attiogbe, Messan, Yaka, Kossi Jeff, Ekon, Agbégnigan Lorette, Bimba, Julien, Dagnra, Claver Anoumou, Tegueni, Kokou Dominique, Agboyibor, Mawuényégan K, Eubanks, August, Fayé-Ketté, Hortense, Koné, Amadou, Diandé, Souba, Dagnra, Claver A, and Dah, Ter Tiero E

Published
2021
Full Text
View/download PDF

16. Antibacterial mouthwash to prevent sexually transmitted infections in men who have sex with men taking HIV pre-exposure prophylaxis (PReGo): a randomised, placebo-controlled, crossover trial

Author

Van Dijck, Christophe, Tsoumanis, Achilleas, Rotsaert, Anke, Vuylsteke, Bea, Van den Bossche, Dorien, Paeleman, Elke, De Baetselier, Irith, Brosius, Isabel, Laumen, Jolein, Buyze, Jozefien, Wouters, Kristien, Lynen, Lutgarde, Van Esbroeck, Marjan, Herssens, Natacha, Abdellati, Said, Declercq, Steven, Reyniers, Thijs, Van Herrewege, Yven, Florence, Eric, and Kenyon, Chris

Published
2021
Full Text
View/download PDF

17. No Evidence for Clade I Monkeypox Virus Circulation, Belgium

Author

Liesenborghs, Laurens, Coppens, Jasmine, Van Dijck, Christophe, Brosius, Isabel, De Baetselier, Irith, Vercauteren, Koen, and Van Esbroeck, Marjan

Subjects
Human monkeypox -- Analysis, Health, World Health Organization
Abstract

To the Editor: As professionals involved in the mpox response in Belgium, we read with concern the report by Kibungu et al. on a clade I mpox outbreak linked to [...]

Published
2024
Full Text
View/download PDF

18. The HepHIV 2023 Madrid conference: A call to action for political leadership in reaching the sustainable development goals on earlier testing and linkage to care for HIV, viral hepatitis, and sexually transmitted infections.

Author

Simões, Daniel, Raben, Dorthe, Moran, Alejandro Bertó, Imaz, Arkaitz, Stengaard, Annemarie Rinder, Raahauge, Anne, Sullivan, Ann K., Vaughan, Elena, Brännström, Johanna, De Baetselier, Irith, Platteau, Tom, Casabona, Jordi, Del Amo, Julia, Collins, Ben, James, Cary, Onyango, Denis, Duffell, Erika, Rockstroh, Jürgen, Cosmaro, Lella, and Noori, Teymur

Subjects
DIAGNOSIS of HIV infections, SEXUALLY transmitted disease diagnosis, HEALTH services accessibility, VIRAL hepatitis, INTERPROFESSIONAL relations, RESOURCE allocation, LEADERSHIP, CONFERENCES & conventions, GOAL (Psychology), MEDICAL screening, EARLY diagnosis, PRACTICAL politics, DISCRIMINATION (Sociology), HEALTH equity, SOCIAL stigma, INTEGRATED health care delivery
Abstract

Introduction and Objectives: The HepHIV 2023 Conference, held in Madrid in November 2023, highlighted how Europe is not on track to meet the United Nations (UN) sustainable development goals and Joint UN Programme on HIV/AIDS (UNAIDS) targets. This article presents the outcomes of the conference, which focus on ways to improve testing and linkage to care for HIV, viral hepatitis, and other sexually transmitted infections. HIV‐related stigma and discrimination, a major barrier to progress, was a key concept of the conference and on the agenda of the Spanish Presidency of the European Union. Methods: The HepHIV 2023 organizing committee, alongside the Spanish Ministry of Health, oversaw the conference organization and prepared the scientific programme based on abstract rankings. Key outcomes are derived from conference presentations and discussions. Results: Conference presentations covered the obstacles that HIV‐related stigma and discrimination continue to pose to access to services, models for data collection to better monitor progress in the future, and examples of legislative action that can be taken at national levels. Diversification of testing approaches was also highlighted, to reach key populations, (e.g. migrant populations), to increase testing offered in healthcare settings (e.g. emergency departments), and to account for different stages of epidemics across the region. Conclusion: With a strong call for intensified action to address the impact of HIV‐related stigma and discrimination on testing uptake, the conference concluded that strengthened collaboration is required between governments and implementers around testing and linkage to care. There is also an ongoing need to ensure sustainable political commitment and appropriate resource allocation to address gaps and inequalities in access for key populations and to focus on the implementation of integrated responses to HIV, viral hepatitis, and sexually transmitted infections. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

21. High adherence to intermittent and continuous use of a contraceptive vaginal ring among women in a randomized controlled trial in Kigali, Rwanda

Author

Kestelyn, Evelyne, primary, Van Nuil, Jennifer Ilo, additional, Umulisa, Marie Michelle, additional, Umutoni, Grace, additional, Uwingabire, Alice, additional, De Baetselier, Irith, additional, Uwineza, Mireille, additional, Agaba, Stephen, additional, Crucitti, Tania, additional, Delvaux, Thérèse, additional, and van de Wijgert, Janneke H. H. M., additional

Published
2024
Full Text
View/download PDF

22. Antimicrobial-resistant Neisseria gonorrhoeae in Europe in 2020 compared with in 2013 and 2018: a retrospective genomic surveillance study

Author

Golparian, Daniel, primary, Cole, Michelle J, additional, Sánchez-Busó, Leonor, additional, Day, Michaela, additional, Jacobsson, Susanne, additional, Uthayakumaran, Thinushaa, additional, Abad, Raquel, additional, Bercot, Beatrice, additional, Caugant, Dominique A, additional, Heuer, Dagmar, additional, Jansen, Klaus, additional, Pleininger, Sonja, additional, Stefanelli, Paola, additional, Aanensen, David M, additional, Bluemel, Benjamin, additional, Unemo, Magnus, additional, Stadlbauer, Silke, additional, Indra, Alexander, additional, De Baetselier, Irith, additional, Vanden Berghe, Wim, additional, Lecompte, Amaryl, additional, Hunjak, Blaženka, additional, Blažić, Tatjana Nemeth, additional, Maikanti-Charalambous, Panayiota, additional, Pieridou, Despo, additional, Zákoucká, Hana, additional, Žemličková, Helena, additional, Hoffmann, Steen, additional, Cowan, Susan, additional, Schwartz, Lasse Jessen, additional, Peetso, Rita, additional, Epstein, Jevgenia, additional, Viktorova, Jelena, additional, Bébéar, Cécile, additional, Lot, Florence, additional, Torvikoski, Jukka, additional, Korhonen, Suvi, additional, Buder, Susanne, additional, Miriagou, Vivi, additional, Siatravani, Eirini, additional, Magaziotou, Ioanna, additional, Paparizou, Eleni, additional, Balla, Eszter, additional, Dudás, Mária, additional, Ásmundsdóttir, Lena Rós, additional, Hauksdóttir, Guðrún Svanborg, additional, Gudnason, Thorolfur, additional, Thordardottir, Marianna, additional, Colgan, Aoife, additional, Crowley, Brendan, additional, Saab, Sinéad, additional, Keane, Maeve, additional, Carannante, Anna, additional, Parodi, Patrizia, additional, Pakarna, Gatis, additional, Nikiforova, Raina, additional, Bormane, Antra, additional, Dimina, Elina, additional, Barbara, Christopher, additional, Mifsud, Francesca, additional, Cassar, Robert, additional, Haider, Julie, additional, Van Dam, Alje, additional, Van Benthem, Birgit, additional, Visser, Maartje, additional, Linde, Ineke, additional, Kløvstad, Hilde, additional, Caugant, Dominique, additional, Bergheim, Thea, additional, Młynarczyk-Bonikowska, Beata, additional, Azevedo, Jacinta, additional, Borrego, Maria-José, additional, Nascimento, Marina Lurdes Ramos, additional, Pavlik, Peter, additional, Klavs, Irena, additional, Murnik, Andreja, additional, Kustec, Tanja, additional, Vodičar, Polona Maver, additional, Vázquez Moreno, Julio, additional, Diaz, Asuncion, additional, Abad Torreblanca, Raquel, additional, and Velicko, Inga, additional

Published
2024
Full Text
View/download PDF

26. Estimation of antimicrobial resistance of Mycoplasma genitalium, Belgium, 2022

Author

De Baetselier, Irith, primary, Smet, Hilde, additional, Kehoe, Kaat, additional, Loosen, Imelda, additional, Reynders, Marijke, additional, Mansoor, Iqbal, additional, Filippin, Lorenzo, additional, Cauchie, Mathieu, additional, Van Even, Ellen, additional, Makki, Nadia, additional, Schiettekatte, Gilberte, additional, Vandewal, Wouter, additional, Glibert, Bart, additional, Matheeussen, Veerle, additional, Van der Beken, Yolien, additional, Cartuyvels, Reinoud, additional, Steyaert, Sophia, additional, Lemmens, Ann, additional, Garrino, Maria-Grazia, additional, Paridaens, Henry, additional, Lazarova, Elena, additional, Lissoir, Bénédicte, additional, Deffontaine, Marine, additional, Heinrichs, Amélie, additional, Saegeman, Veroniek, additional, Padalko, Elizaveta, additional, Lecompte, Amaryl, additional, Vanden Berghe, Wim, additional, Kenyon, Chris, additional, and Van den Bossche, Dorien, additional

Published
2024
Full Text
View/download PDF

27. High tetracycline resistance percentages in Neisseria gonorrhoeae in Europe: is doxycycline post-exposure prophylaxis unlikely to reduce the incident gonorrhoea cases?

Author

Unemo, Magnus, primary, Cole, Michelle J., additional, Kodmon, Csaba, additional, Day, Michaela, additional, Jacobsson, Susanne, additional, Balla, Eszter, additional, Bercot, Beatrice, additional, Borrego, Maria José, additional, Caugant, Dominique, additional, Cole, Michelle, additional, Crowley, Brendan, additional, De Baetselier, Irith, additional, Heuer, Dagmar, additional, Miriagou, Vivi, additional, Młynarczyk-Bonikowska, Beata, additional, Pavlik, Peter, additional, Philipova, Ivva, additional, Schindler, Stefanie, additional, Schröder, Daniel, additional, Torreblanca, Raquel Abad, additional, Tõnsau, Kairi, additional, Unemo, Magnus, additional, Van Dam, Alje, additional, Vella, Francesca, additional, Vodičar, Polona Maver, additional, and Zákoucká, Hana, additional

Published
2024
Full Text
View/download PDF

29. Potential determinants of the decline in mpox cases in Belgium:A behavioral, epidemiological and seroprevalence study

Author

De Vos, Elise, Van Gestel, Liesbeth, Brosius, Isabel, Kenyon, Chris, Vuylsteke, Bea, De Baetselier, Irith, Mariën, Joachim, Bangwen, Eugene, Couvreur, Simon, Lecompte, Amaryl, Van Beckhoven, Dominique, Hoorelbeke, Bart, Verstrepen, Babs E., Zaeck, Luca M., de Vries, Rory D., Geurts van Kessel, Corine H., Hens, Niel, Ariën, Kevin K., Vercauteren, Koen, Van Esbroek, Marjan, Van Dijck, Christophe, Liesenborghs, Laurens, De Vos, Elise, Van Gestel, Liesbeth, Brosius, Isabel, Kenyon, Chris, Vuylsteke, Bea, De Baetselier, Irith, Mariën, Joachim, Bangwen, Eugene, Couvreur, Simon, Lecompte, Amaryl, Van Beckhoven, Dominique, Hoorelbeke, Bart, Verstrepen, Babs E., Zaeck, Luca M., de Vries, Rory D., Geurts van Kessel, Corine H., Hens, Niel, Ariën, Kevin K., Vercauteren, Koen, Van Esbroek, Marjan, Van Dijck, Christophe, and Liesenborghs, Laurens

Abstract

Objectives: The 2022 mpox epidemic reached a peak in Belgium and the rest of Europe in July 2022, after which it unexpectedly subsided. This study investigates epidemiological, behavioral, and immunological factors behind the waning of the epidemic in Belgium. Methods: We investigated temporal evolutions in the characteristics and behavior of mpox patients using national surveillance data and data from a prospective registry of mpox patients in the Institute of Tropical Medicine (Antwerp). We studied behavioral changes in the population at risk using a survey among HIV-preexposure prophylaxis (PrEP) users. We determined the seroprevalence of anti-orthopoxvirus antibodies among HIV-PrEP users across four-time points in 2022. Results: Mpox patients diagnosed at the end of the epidemic had less sexual risk behavior compared to those diagnosed earlier: they engaged less in sex at mass events, had fewer sexual partners, and were less likely to belong to the sexual network's central group. Among HIV-PrEP users there were no notable changes in sexual behavior. Anti-orthopoxvirus seroprevalence did not notably increase before the start of national vaccination campaigns. Conclusion: The observed changes in group immunity and behavior in the population at greater risk of exposure to mpox seem unable to explain the waning of the mpox epidemic. A change in the profile of mpox patients might have contributed to the decline in cases.

Published
2024

30. High adherence to intermittent and continuous use of a contraceptive vaginal ring among women in a randomized controlled trial in Kigali, Rwanda

Author

Epi Infectieziekten Team 1b, Infection & Immunity, JC onderzoeksprogramma Infectieziekten, Kestelyn, Evelyne, Van Nuil, Jennifer Ilo, Umulisa, Marie Michelle, Umutoni, Grace, Uwingabire, Alice, De Baetselier, Irith, Uwineza, Mireille, Agaba, Stephen, Crucitti, Tania, Delvaux, Thérèse, van de Wijgert, Janneke H H M, Epi Infectieziekten Team 1b, Infection & Immunity, JC onderzoeksprogramma Infectieziekten, Kestelyn, Evelyne, Van Nuil, Jennifer Ilo, Umulisa, Marie Michelle, Umutoni, Grace, Uwingabire, Alice, De Baetselier, Irith, Uwineza, Mireille, Agaba, Stephen, Crucitti, Tania, Delvaux, Thérèse, and van de Wijgert, Janneke H H M

Published
2024

35. The Prevalence of Antibiotic Tolerance in Neisseria gonorrhoeae Varies by Anatomical Site.

Author

Balduck, Margaux, Strikker, Akim, Gestels, Zina, Abdellati, Saïd, Van den Bossche, Dorien, De Baetselier, Irith, Kenyon, Chris, and Manoharan-Basil, Sheeba Santhini

Subjects
NEISSERIA gonorrhoeae, DRUG resistance in microorganisms, ANTIBIOTICS, CEFTRIAXONE, CIPROFLOXACIN, AZITHROMYCIN
Abstract

Background: Tolerance enables bacteria to survive intermittent antibiotic exposure without an increase in antimicrobial susceptibility. In this study, we investigated the presence of tolerance to three antimicrobials, ceftriaxone, azithromycin and ciprofloxacin, in clinical isolates and the WHO (World Health Organization) reference panel of Neisseria gonorrhoeae. Methods: We used the modified tolerance disk (TD test) to assess for tolerance to ceftriaxone, azithromycin and ciprofloxacin in 14 WHO reference strains and 62 N. gonorrhoeae clinical isolates—evenly divided between anorectal and urogenital infections. The isolates underwent a three-step incubation process wherein the isolates were exposed to an antibiotic disk for 20 h of incubation (Step I), followed by the replacement of the antibiotic disk with a nutrient disk for overnight incubation (Step II) and additional overnight incubation with extra nutrients (Step III). Results: A total of 4 of the 62 clinical anorectal isolates and none of the urogenital isolates exhibited tolerance to azithromycin (p = 0.033). Tolerance to ceftriaxone and ciprofloxacin was observed in eight and four isolates, respectively, with no difference between infection sites. Tolerance was also detected in 8 (K, M, N, O, P, U, V, W) out of the 14 WHO reference strains, with varying patterns of tolerance to ceftriaxone (n = 8), ciprofloxacin (n = 2) and azithromycin (n = 1). Conclusions: This study identified ceftriaxone, azithromycin and ciprofloxacin tolerance in clinical and WHO reference N. gonorrhoeae isolates. Azithromycin tolerance was more common in anorectal than urogenital infections. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

41. Daily and event-driven pre-exposure prophylaxis for men who have sex with men in Belgium: results of a prospective cohort measuring adherence, sexual behaviour and STI incidence

Author

Vuylsteke, Bea, Reyniers, Thijs, De Baetselier, Irith, Nostlinger, Christiana, Crucitti, Tania, Buyze, Jozefien, Kenyon, Chris, Wouters, Kristien, and Laga, Marie

Subjects
Sexually transmitted diseases -- Prevention -- Analysis -- Health aspects -- Measurement, Prophylaxis -- Analysis -- Health aspects -- Measurement, Disease transmission -- Prevention -- Analysis -- Health aspects -- Measurement, HIV tests -- Analysis -- Health aspects -- Measurement, Emtricitabine -- Analysis -- Health aspects -- Measurement, HIV -- Prevention -- Analysis -- Health aspects -- Measurement, Infection -- Prevention -- Analysis -- Health aspects -- Measurement, Hepatitis C -- Prevention -- Analysis -- Health aspects -- Measurement, Sexually transmitted disease prevention -- Analysis -- Health aspects -- Measurement, Health
Abstract

Introduction: Pre-Exposure Prophylaxis (PrEP) is highly effective in reducing the risk for HIV infection among men who have sex with men (MSM) and may have an important impact in slowing down the HIV epidemic. Concerns remain however about low adherence, increased risk behaviour and reduced condom use when using PrEP. The aim of this study was to assess these factors prospectively among MSM using daily and event-driven PrEP in Belgium. Methods: An open-label prospective cohort study was conducted from October 2017 to May 2018 at the Institute of Tropica Medicine, in Antwerp, Belgium. At enrolment, MSM at high risk for HIV chose between daily or event-driven PrEP. They were allowed to switch regimens or stop taking PrEP at each of their tri-monthly visits. Data were collected on an electronic case report form, web-based diary and self-administered questionnaire. Screening for HIV and other Sexually Transmitted Infections (STIs) was also performed. Results: Two hundred MSM were followed up for a total duration of 318 person-years. At month 18, 75.4% of the participants were on daily and 24.6% were on event-driven PrEP. The mean proportion of covered sex acts by PrEP for the complete follow-up period was 91.5% for all participants, 96.5% for daily and 67.0% for event-driven PrEP use. The number of casua and anonymous sex partners was significantly higher for daily users, as compared with event-driven users, but did not change over time. In contrast, the mean proportion of condomless receptive anal intercourse with casual and anonymous partners increased significantly during follow-up, for both daily and event-driven use (p < 0.0001 for all 4 trends). No new HIV infection was diagnosed during follow-up. The incidence of bacterial STIs was 75.4 per 100 person-years (95% CI 63.8 to 89.1). We did not detect a significant change in N. gonorrhoeae/C. trachomatis incidence over time. The incidence of hepatitis C was 2.9 per 100 person-years. Conclusions: PrEP is an effective and well adopted HIV prevention tool for MSM in Belgium. Participants adapted daily and event-driven regimens to their own needs and were able to adapt their PrEP adherence to risk exposure. Keywords: PrEP; HIV prevention; MSM; Belgium; adherence; STI; event-driven, 1 | INTRODUCTION Pre-Exposure Prophylaxis (PrEP) using daily oral tenofovir disoproxil fumarate and emtricitabine (TDF/FTC) is highly effective in reducing the risk for HIV infection among men who have sex [...]

Published
2019
Full Text
View/download PDF

44. Does screening for Neisseria gonorrhoeae and Chlamydia trachomatis affect the incidence of these infections in men who have sex with men taking HIV pre-exposure prophylaxis (PrEP) ? Results from a randomized, multicentre controlled trial (the Gonoscreen study)

Author

Vanbaelen, Thibaut, primary, Tsoumanis, Achilleas, additional, Florence, Eric, additional, Van Dijck, Christophe, additional, Huis in 't Veld, Diana, additional, Sauvage, Anne Sophie, additional, Herssens, Natacha, additional, De Baetselier, Irith, additional, Rotsaert, Anke, additional, Verhoeven, Veronique, additional, Henrard, Sophie, additional, Van Herrewege, Yven, additional, Van den Bossche, Dorien, additional, Goffard, Jean-Christophe, additional, Padalko, Elizaveta, additional, Reyniers, Thijs, additional, Vuylsteke, Bea, additional, Hayette, Marie-Pierre, additional, Libois, Agnes, additional, and Kenyon, Chris, additional

Published
2023
Full Text
View/download PDF

47. High tetracycline resistance percentages in Neisseria gonorrhoeae in Europe: is doxycycline post-exposure prophylaxis unlikely to reduce the incident gonorrhoea cases?

Author

Balla, Eszter, Bercot, Beatrice, Borrego, Maria José, Caugant, Dominique, Cole, Michelle, Crowley, Brendan, Day, Michaela, De Baetselier, Irith, Heuer, Dagmar, Jacobsson, Susanne, Kodmon, Csaba, Miriagou, Vivi, Młynarczyk-Bonikowska, Beata, Pavlik, Peter, Philipova, Ivva, Schindler, Stefanie, Schröder, Daniel, Torreblanca, Raquel Abad, Tõnsau, Kairi, Unemo, Magnus, Van Dam, Alje, Vella, Francesca, Vodičar, Polona Maver, Zákoucká, Hana, and Cole, Michelle J.

Published
2024
Full Text
View/download PDF

49. Estimation of the real magnitude of antimicrobial resistance of Mycoplasma genitalium in Belgium by implementing a prospective surveillance programme.

Author

De Baetselier, Irith, primary, Smet, Hilde, additional, Kehoe, Kaat, additional, Loosen, Imelda, additional, Reynders, Marijke, additional, Mansoor, Iqbal, additional, Filippin, Lorenzo, additional, Cauchie, Matthieu, additional, Van Even, Ellen, additional, Makki, Nadia, additional, Schiettekatte, Gilberte, additional, Vandewal, Wouter, additional, Glibert, Bart, additional, Matheeussen, Veerle, additional, Van der Beken, Yolien, additional, Cartuyvels, Reinoud, additional, Steyaert, Sophia, additional, Lemmens, Ann, additional, Garrino, Maria-Grazia, additional, Paridaens, Henry, additional, Lazarova, Elena, additional, Lissoir, Benedicte, additional, Deffontaine, Marine, additional, Heinrichs, Amelie, additional, Padalko, Elizaveta, additional, Saegeman, Veroniek, additional, Lecompte, Amaryl, additional, Berghe, Wim Vanden, additional, Kenyon, Chris, additional, and Van den Bossche, Dorien, additional

Published
2023
Full Text
View/download PDF

50. Effect of screening for Neisseria gonorrhoeaeand Chlamydia trachomatison incidence of these infections in men who have sex with men and transgender women taking HIV pre-exposure prophylaxis (the Gonoscreen study): results from a randomised, multicentre, controlled trial

Author

Vanbaelen, Thibaut, Tsoumanis, Achilleas, Florence, Eric, Van Dijck, Christophe, Huis in 't Veld, Diana, Sauvage, Anne-Sophie, Herssens, Natacha, De Baetselier, Irith, Rotsaert, Anke, Verhoeven, Veronique, Henrard, Sophie, Van Herrewege, Yven, Van den Bossche, Dorien, Goffard, Jean-Christophe, Padalko, Elizaveta, Reyniers, Thijs, Vuylsteke, Bea, Michel, Charlotte, Hayette, Marie-Pierre, Libois, Agnes, and Kenyon, Chris

Abstract

Guidelines recommend screening for Neisseria gonorrhoeaeand Chlamydia trachomatisat three anatomical sites (urethra, anus, and pharynx) every 3 months (3 × 3) in men who have sex with men (MSM) and transgender women taking HIV pre-exposure prophylaxis (PrEP). We present the first randomised controlled trial to compare the effect of screening versus non-screening for N gonorrhoeaeand C trachomatison the incidence of these infections in MSM and transgender women taking PrEP.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results